
|Articles|August 1, 2002
High conformal RT doses improve PSA, increase toxicity
Orlando, FL-Conformal radiotherapy to the prostate with isocenterdoses of 78 Gy lowers biochemical failure by at least 6% at 6 years, andby as much as 19% for men at higher risk of cancer relapse. But the costis a 14% increase in mild to moderate risk of rectal toxicity, accordingto two reports presented at the American Society of Clinical Oncology annualmeeting.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
4
FDA approves first-line Zenflow system for the treatment of BPH
5















